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Abstract
Health economic evaluation that encompasses decision analytic model is a beneficial approach 
for assisting decision maker to choose the best health intervention for patients. Decision analytic model 
has been increasingly applied in health economic evaluation. This mathematical approach is mostly 
used for conducting cost-effectiveness of healthcare interventions.
Decision tree and Markov model has been widely applied in the past 20 years. Decision tree is 
the simplest form of decision model that drawn by the series of branches and clear pathways. Meanwhile, 
Markov model is one of the powerful approaches that employ stochastic process in health economic eval-
uation. This paper describes the applications of those two models in tobacco cessations, specifically for 
pharmacological interventions.
First, decision tree for cost-effectiveness of smoking cessation program with pharmacist and thera-
pies interventions compared to no program or self-aid cessation. Second, the application of Markov model 
estimates cost-effectiveness of veranicline, in comparison to bupropion. Markov model is constructed with 
morbidity and mortality states that consists of: well/no morbidities, lung cancer, COPD, stroke, myocar-
dial infarction, and dead. This paper provides step by step of populating and constructing the model-with 
some modification of data. Several sections discuss the understanding of transition probabilities, costs data, 
cohort simulation, and the role of sensitivity analysis. Other models, despite deterministic approach, prob-
abilistic approach are also reviewed.
Both of models had both advantages and limitation that analysts should be aware of. Translating the 
‘real world’ to mathematical model yields beneficial and insightful information for analysts. In addition, it 
could fulfill the need of evidence-based policy by decision maker. From simulation, the model may easy to 
be replicated-with appropriate context to generate evidence related health and costs.
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Introduction
Health economic evaluation is a general framework to aid decision maker with best avail-
able evidence in terms of priority setting and choosing particular health technologies (Shiell et 
al. 2002). This is one of pivotal aspects for decision making that commonly related to funding, 
reimbursement or regulatory of health intervention, with increasing challenges of finite resources 
available (Morris et al. 2007; Hjelmgren et al. 2001). 
Decision analytic model can be used in health economic evaluation; it is widely applied to 
estimate cost-effectiveness of healthcare interventions (Sox et al. 1988; Buxton et al.1997; Hun-
nink et al. 2001). This essential technique is defined as a systematic approach on synthesizing 
information from multiple sources and applying mathematical relationship to answer decision 
problems, allowing its variability and uncertainty. Expected costs and possible consequences of 
all available options are compared (Briggs et al. 2006; Gray et al. 2010). In particular situation, 
economic evaluation is increasingly conducted alongside clinical trial. However, the results from 
this economic evaluation do not always able to inform decision related reimbursement (Sculpher 
et al. 2006). Decision analytic model therefore can be beneficial to resolve the limitations in clin-
ical trial.
Generally, there are several circumstances when decision analytic modeling in health eco-
nomic evaluation is very useful. First, when Randomized Clinical Trials (RCTs) could not be 
undertaken due to costs, time, or other reasons. Hence, modeling techniques can be applied by 
synthesizing all relevant information from various sources, not only from primary data (Karnon 
and Brown, 1998). Second, RCTs remain crucial for efficacy evidence. However, it might not com-
pare all relevant alternatives and provide appropriate time horizon. In health economic evaluation, 
time horizon should be long enough to capture the magnitude of costs and benefits among alter-
natives. (Drummond et al., 2005; Briggs et al., 2006). Third, final endpoints evidence is difficult 
to be achieved, for instance: mortality and long-term morbidity. It is related to short time horizon 
in clinical trials, mostly RCTs are concluded up to intermediate endpoints. Furthermore, by devel-
oping a model, the results can be extended (Briggs et al., 2006). Moreover, Sculpher et al. (1997) 
explained four major stages in economic evaluation process, and decision analytic model assigned 
prominent role in each of those steps. Therefore, decision analytic model is able to sufficiently an-
swer the resource allocation question, while all information about cost and consequences become 
barriers in primary clinical research such as RCTs. As powerful tool in economic evaluation, mod-
eling is structuring evidence both clinical and economics outcomes, simplifying representation of 
reality. It thus beneficial to generate relevant evidence that highly required by decision makers.
There are some alternatives modeling approach that can be used for estimating cost-effec-
tiveness of health interventions. For example: dynamic models, discrete event simulations (DES), 
and patient level simulations (Petrou and Gray, 2011). However, this paper only discusses decision 
tree and Markov model application, since these two models are frequently applied in economic 
evaluation (Buxton et al., 1997; Karnon and Brown 1998). Author discusses the example of tobac-
co program as well as pharmacological therapies in tobacco cessation, in this example: veranicline, 
bupropion. The costs and outcomes value have been determined as instances. Models in this paper 
are structured by referring from previous studies, indeed with some modifications. Author will 
frequently use terms Cost-effectiveness Analysis (CEA) and Cost Utility Analysis(CUA). Illus-
trations of these methods can be found in publication by Drummond et al. (2005). This paper is 
divided into several sections that cover stages on designing and conducting simple decision tree 
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and Markov model for pharmacological interventions in smoking cessation.
This paper neither demonstrates modeling choice nor provides ideal good structure that 
should be followed on tobacco cessation cases. Models are characterized depend on research or 
policy question, modeler, and decision maker consideration, not only technically applying math-
ematical operations. It should be noted that this paper focuses on outlining the basic theory and 
aim to familiarize unexposed audience with basics modeling applications as abstractions of reality. 
Decision rules
Before going to further parts, this section covers the decision rules and general rationale of 
conducting CEA/CUA for making sense the final resources after applying decision models. Deci-
sion makers in health sector often face a dilemma for choosing health intervention. New treatment/
health technology is often more effective than current/standard treatment, however it is inevitably 
more expensive. Health economists are interested in considering of “how much do we get the 
benefit for additional cost or the money spent?” Value for money of new intervention furthermore 
is summarized by Incremental Cost-Effectiveness Ratio (ICER) (Owens, 1998; Jefferson, 2000; 
Cohen and Reynolds, 2008).
The concept of cost, effect, effectiveness and its linkage to ICER concepts are divided into 
four main rules (O’Brien et al. 1994; Briggs and Tambour 1998). From two therapies that are com-
pared, one new treatment and a comparator or familiarly named as existing treatment represented 
by “A” and “B”, respectively. Mean of treatment’s costs denoted byμ_cA andμ_cB. Similarly, 
effects are denoted by μ_eA and μ_eB. It describes below:
1. μ_cA -  μ_cB< 0 ; μ_eA -  μ_eB> 0   ; dominance, accept new treatment
2. μ_cA -  μ_cB> 0 ; μ_eA -  μ_eB< 0   ; dominance, reject new treatment
3. μ_cA - μ_cB> 0 ; μ_eA -  μ_eB> 0 ; trade-off (consider magnitude of ratio of differenc-
es in cost to differences in effect; or additional costs relative to additional effectiveness)
4. μ_cA -  μ_cB< 0 ; μ_eA -  μ_eB< 0 ; trade-off (consider magnitude of ratio of differenc-
es in cost to differences in effect, cost-saving to it reduced effectiveness)
Those four points are in relation to four quadrants of cost-effectiveness plane. It is common-
ly used for presenting cost-effectiveness results that described and discussed in almost economic 
evaluation results. The condition number 1 demonstrates that we accept new treatment when it is 
more effective and less costly compared to existing treatment. In contrast, condition number 2, 
when new treatment is more costly and less effective, so then clearly we reject it. However, when a 
new treatment is more effective but also it is more expensive, then judgment should be made. This 
is the condition when ICER is playing its role, providing the summary of cost-effectiveness of new 
intervention compared to current intervention/treatment(s) with equation: 
ICER= (μcA-μcB)/(μeA- μcB) = μΔc/μΔe < λ
Therefore, ICER is simply the ratio of both differences in costs and effects. The λ(lambda) 
represents maximum acceptable cost-effectiveness ratio or ceiling ratio. Several countries have 
produced lamda to support their decision related to new health intervention (Mc Cabe et al. 2008; 
Grosse, 2008; Shiroiwa et al. 2010; Neumann et al. 2014). If the ICER is less than the value of λ, 
it is concluded that the intervention is potentially be accepted. 
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Defining questions 
The first step for structuring the decision model is specifying the decision problem. Pop-
ulation, interventions, comparators, as well as clinical and economic outcomes should be clearly 
identified (Briggs et al. 2006; Drummond et al. 2005; Gray et al. 2010). In this case, for instance, 
we will discuss modeling method for cost-effectiveness/cost-utility analysis of smoking cessation 
program with pharmacological therapies such as: varenicline and bupropion. In addition, perspec-
tive of evaluation should be considered, why the intervention is being evaluated, costs incurred, 
and for whom the result required and may support the decision. The perspectives reflect the pur-
pose of evaluation (Byford and Raftery, 1998; Jonsson, 2009; Hjelmegren et al.  2001).
Appropriate decision model should be structured and developed by clear understanding 
about the problems. Several guidelines provide details of good practices in constructing the mod-
el (Weinstein et al. 2003; Roberts et al. 2012). Parameters choice, sources of data and evidence 
synthesis important as model input also available in standing alone publication. (Caro et al. 2010; 
Briggs et al. 2012). In this paper, all the data has been given and we directly head to explanation 
of model structure. However, author provides the schematic of design and conducting decision 
analytic model in figure 1. It is a complete visual illustration of decision analysis process. This 
illustration is summarized and modified according several publications (Briggset al. 2006; Marti-
kainen, 2008; Gray et al. 2010; Roberts et al. 2012; Briggs et al. 2012).
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Structuring and analyzing the models
Decision Tree
Smoking cessation can be classified into two types behavioral therapies and pharmacother-
apies. Pharmacotherapies interventions in smoking cessation can be classified as nicotine replace-
ment therapy (NRT) and non-nicotine based medications (bupropion and varenicline) (Ruger and 
Razar, 2012). The first model will discuss the cost-effectiveness of community pharmacy on smok-
ing cessation program. We will estimate the cost-effectiveness of establishing smoking cessation 
programs, medications compared to non-pharmacy based program.
In decision analytical modeling, the simplest form of model is decision tree (Karnon and 
Brown, 1998). Decision tree illustrates alternatives and its events that represent by pathways (figure 
2.). There are several nodes in a decision tree. The “square” node represents the decision question, 
in this case pharmacological-smoking cessation program versus no program. This is the simplest 
scenario of a decision tree. In reality, the comparators are probably more than one, such as tobacco 
bans or other considerable programs. Events or morbidities in a decision tree are represented by 
“circular” symbols. “Triangular” or terminal nodes are placed in the end of each event pathways, 
where model stopped. 
The set of alternatives in a decision tree should be “mutually exclusive”. It means that two 
events could not occur simultaneously (Briggs et al. 2006, Petrou and Gray 2011). Probabilities of 
events and costs are incorporated in each pathway. The probability shows the proportion of pa-
tients’ progression, and in each alternative it should be summed as exactly 1. 
The decision tree structure is adapted from study that compares a pharmacist-managed 
smoking-cessation program with a self-directed quit attempt. The events from therapy strategies 
are modified and simplified (Figure 2.) (Tran et al. 2002; Bauld et al. 2011). A comparator or no 
program means there is no aid from a pharmacist in smoking cessation. The data in this model is 
assumed primary data. Costs incurred are cost related to intervention, with payer perspective. This 
model assumes that in six months, the program may generate two conditions, smokers attempt to 
quit smoking or remain continue to smoke, with events of their health condition, persistent cough.
There are two strategies in this model. Costs are assigned in each pathway. The effectiveness 
of intervention is illustrated on each event, having persistent cough or not. For instance, the proba-
bilities 0.30, indicating that 30% of patients who joined the program with medications attempted to 
quit smoking.  The final result is cost per case avoided. In the end of the decision tree, the expected 
value of costs and outcomes are assigned, ICER therefore can be calculated.
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The summary of calculation is briefly presented below:







A $200 0.30x0.70= 0.21 $       42 $   222.5/0.21= $1,059.5
B $275 0.30x0.30= 0.09 $       24.75
C $200 0.70x0.70= 0.49 $        98
D $275 0.70x0.30= 0.21 $       57.75
Total          1.00 $      222.5
No program 
E $100 0.05x0.70= 0.04 $        4 $  117.5/0.04= $2,937.5
F $150 0.05x0.30= 0.02 $        3
G $100 0.95x0.70= 0.67 $      67
H $150 0.95x0.30= 0.29 $      43.5
Total 1.00 $    117.5
The average cost-effectiveness ratio (ACER) is derived from expected costs per effective-
ness, in this case per quit smoking with no persistent cough. We can conclude that ACER of no 
program is higher than providing program $2,937.5. Furthermore, to estimate ICER, as formulat-
ed above, the ICER will be (222.5-117.5) / (0.21-0.04) resulting $617.65 per quit attempt (with 
no persistent cough). To conclude whether program is potentially effective, analysts can use their 
acceptable maximum of cost-effectiveness ratio (λ).
Applying decision tree allows the less complicated scenarios, simplicity, as well as trans-
parency (Karnon and Brown, 1998; Petiti, 1999). We can build a set of alternatives with clear 
pathways. However, there is a limitation to deal with time dependent in economic evaluation 
such as applying discounting. The decision tree above looks simple because it is applying short-
term outcome and short time horizon (less than one year), with unnecessary discounting appli-
cation. The smoking cases often have outcome that tend to be recursive, or patients will survive 
with a particular condition that may take longer than one year. In terms of recurrent events such 
as chronic diseases, the analysis will be more complicated. Decision tree become “bushy” and 
having long-complex pathways. (Karnon and Brown, 1998; Briggs et al. 2006; Petrou and Gray, 
2011)
Markov model
The Markov model was first developed by Russian mathematician, Andrey Markov 
(1856-1922). It is a random process that encounters transition from one state to another state. 
This model is beneficial for ongoing events over time and risks exposure (Stahl, 2008).  For 
instance, we will discuss lung cancer as clinical conditions that are experienced by patients, risks 
may change over time and Markov model can be useful for this case. 
As a model alternative in health economic evaluation, the Markov model can deal with 
more complex decision problems and is able to be applied for longer pathways/sequences, partic-
ularly for recurrent outcomes (Stahl, 2008; Sato and Zouain, 2010). Markov state refers patients 
are staying in one health state and can move from their current state to another state over discrete 
time period. The movements among states are attributed by transition probability. Number of 
states in Markov model are determined depend on decision problem. Moreover, time horizon is 
represented by distinctive “cycles”, it could be monthly or annual cycle. (Sonneberg and Beck, 
1993; Briggs and Sclupher, 1998; Briggs, 2006; Nikfar, 2012). The first state in Markov process 
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is commonly of well condition or without morbidity, then progression states and finally death, or 
familiarly known as “absorption state”.
We will discuss the application of Markov model for estimating the cost-effectiveness of 
Veranicline compared to Bupropion. This is based on condition that Varenicline has higher effec-
tiveness to support smoking cessation compared to another pharmacological intervention (Mah-
moudi et al, 2012). Structure of this model is adapted and modified according to publication that 
apply BENESCO (Benefits of Smoking Cessation on Outcomes model) and Quit Benefit Model 
(QBM) (Hurley and Matthews 2007; Bolin et al.  2009).
The first stage in constructing Markov model after specifying decision problem is de-
fining the states. States must represent clinical and economic effects of a disease. In this model, 
states consist of: no-morbidity/well, COPD (Chronic Obstructive Pulmonary Disease), lung can-
cer, stroke and MI (Myocardial Infarction). Four states in progressive states assume that model 
will be simulated for 20 years, and post-morbidities state transition probability assumed similar 
for first and second year onwards. The Markov model is presented in Figure 3, and to translate 
and to understand the transition probabilities, author provide the transition matrix on table 2. 
Figure 3. Markov modelfor cost-utility analysis of Veranicline versus Bupropion
Overall, there are six health states on this Markov model. Patients start the model with 
“well” states, or without morbidity, and can move to particular states such as stroke, COPD, lung 
cancer and MI or death. The next stage is incorporating input parameters that include transition 
probability, costs, utility and effectiveness. For this model, the effectiveness of intervention is tak-
en from meta analyses, represented with Risk Ratio (RR). 
According to the graph, transition probability initiated with “p” followed by the first letter 
of states. For example: pStoD is for transition probability from stroke state to death state. Transi-
tion probabilities (represented by arrows) are derived from clinical trials, observational studies or 
from systematic reviews. Transition probabilities can be structured by transition probability matrix 
on Table 2. The “loop” symbol means that patients may remain experiencing with health condition 
in that state at specific time before moving to another state. In CUA, sometimes an ideal model is 
added with second year of progressive states such as: post stroke, post MI, second year lung cancer 
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and soon, with an assumption that progressivity of utility values occur in patients after receiving 
the intervention. If the model having extended structure such as post-stroke or post MI, it means 
that we could add new input parameters for second year onwards. 










pNtoS pNtoC pNtoL pNtoMI pNtoD
Stroke 0 1-pstoD 0 0 0 pStoD
COPD 0 0 1-pCtoD 0 0 pCtoD
Lung cancer 0 0 0 1-pLtoD 0 pLtoD
MI 0 0 0 0 1-ptoD ptoD
Death 0 0 0 0 0 pDtoD
The total sum of transition probabilities from initial until end of model must be 1.0. There-
fore, when we calculate the probability of patients who remain in the same states (loop symbol) 
with 1-probabilties. Value “0” simply representing that there is no transition probability from a 
state to another state (see figure 2.)
Sometimes, when it is intended to input parameters such as transition probabilities, for in-
stance from systematic reviews, the confusion between “rate” and “probability” exists. Transition 
probabilities gathered from literature reviews do not exactly reflect the model’s cycle that we con-
struct (Sato, 2010). Rates are potential occurrence of an event in defined population and defined 
time. Meanwhile, probability is assigned values ranging from 0 and 1, representing the “likelihood 
of an event happening over a specific period of time”. To deal with this, rate is possible to be con-
verted to a probability and vice versa (Briggs et al. 2006) where p is the probability, r is the rate 
and t is the time period of an interest:
p=1-exp {-rt}
In the cohort hypothetical simulation, the author desribes how Markov model is running, 
without assigning all input parameters. Details are provided in appendix 1. We only incorporated 
transition probability for every health states, only for familiarizing audience of basic Markov ap-
plication. Unlike a decision tree, Markov model is applicable for applying discounting, which is 
an important factor in health economic evaluation. Additionally, for chronic diseases, the life table 
and survival data are often attached into the model. Quality Adjusted Life Years (QALYs) also 
can be estimated as final results, since in calculating QALYs, valuing quality of life encompasses 
the length of time spent in health states (Briggs, 1998). The cost analysis also has similar method, 
costs are represented in treatment events. With computer application, this complex simulation can 
be handled. After simulating decision analytic model, the final results are ICER, derived from 
differences for both costs and effects/utility, in this case after 20 years cycle. Thus, decision rules 
should be followed. 
33Modelling on Smoking Cessation Putri
Although Markov model application is helpful in decision analytic modeling, there are 
several limitations that we should aware of. Markov has a characteristic of “memory less” (Son-
nenberg, 1993; Briggs, 1998). It means when patient move to another states, the model will have 
no historical memory where patients has come from previous cycles. The population equal in this 
model also with constant risk. Adding additional states and time dependency into transition prob-
ability may possible for the model. Besides, Markov model has greater complexity compared to 
decision tree, however computer software nowadays could help for running this model. 
Handling uncertainty 
Variability, uncertainty and heterogeneity influences the results of decision analytic model, 
these should be handled (Barton et al. 2004). The results of evaluation are depending on uncertain-
ties that related with various factors. This section will focus on short-review for handling uncer-
tainty, before going further, that will be useful to define several types of uncertainty in modeling 
(Briggs et al. 2012). Decision makers needs evidence beyond point estimate of the outcome. The 
uncertainty-surrounding outcome should be explored and reported. Uncertainty may categorized 
as methodological uncertainty, parameter uncertainty, structural uncertainty and generalizability 
(Briggs and Sclupher, 1995). Thus, decision maker can receive more information what factors 
that influence the model and its findings, and increasing the confidence level where they read and 
intend to accept the evaluation results. 
Uncertainty can be handled by performing appropriate sensitivity analysis. There are sev-
eral types of sensitivity analysis (Andronis et al. 2009, Briggs et al. 2012). First, a one-way sen-
sitivity analysis. It is the simplest form of sensitivity analysis, examines impact of the changes 
in model results by varying plausible values range. Tornado diagram is used to visualized this, 
presented with baseline value and range variation in the right and left wings. Second is multi-way 
sensitivity analysis, including two-way sensitivity analysis. This examines relationship of two or 
more parameters, not single parameters like one-way sensitivity analyses. Another type is extreme 
scenario, simply when the parameters or input value of favorable intervention are established to 
provide best and worst case scenario. 
Probabilistic Sensitivity Analysis (PSA) is one type of sensitivity analysis that runs ran-
domly by large number of Monte Carlo simulation (for instance: 10,000 iterative). It is examine 
each input parameters with their probability distributions. It resulted mean cost as well as effec-
tiveness. This approach is preferred to generate cost-effectiveness acceptability curve (Claxton et 
al. 2005; Ades et al. 2006).
Finally, model result and its sensitivity analysis should be presented clearly. It is advisable 
to see guidelines related to full health economics study reporting (Husereau et al. 2013).
Conclusions
Models are chosen, construct and developed based on decision problems and must be ap-
propriate with decision makers’ purpose. All evidence as input parameters are assigned and per-
forms by mathematical operations that translating into model. Furthermore, to decide the set of 
alternatives that should be chosen, the final results of decision analytical models have to follow 
decision rules for cost-effectiveness of health intervention. The explanation in this paper not pro-
viding best practice yet simple example of modeling application, further details and international 
guidelines are available elsewhere (Sclupher et al. 2000; Hjelmegren et al. 2001; Weinstein et al. 
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2003; Philips et al. 2006). 
This paper provides a review and application of decision analytic model in economic eval-
uation, with tobacco cessation examples. Decision tree and Markov model are commonly per-
formed in health economic evaluation, indeed with their advantages and limitations. These two 
model are complements each other. Performing decision analytic modeling is beneficial, specifi-
cally when there are several barriers from clinical trials. Decision tree with its simplicity is able 
to provide clear pathways of decision and for economic evaluation with intermediate outcomes. 
Markov meanwhile has ability to analyze the condition with longer time horizon and expecting 
final outcomes.
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